vs
拜玛林制药（BMRN）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是Rackspace Technology, Inc.的1.3倍（$874.6M vs $682.8M），Rackspace Technology, Inc.净利率更高（-4.8% vs -5.3%，领先0.5%），拜玛林制药同比增速更快（17.0% vs -0.4%），拜玛林制药自由现金流更多（$58.9M vs $56.0M），过去两年拜玛林制药的营收复合增速更高（16.1% vs -0.6%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
BMRN vs RXT — 直观对比
营收规模更大
BMRN
是对方的1.3倍
$682.8M
营收增速更快
BMRN
高出17.4%
-0.4%
净利率更高
RXT
高出0.5%
-5.3%
自由现金流更多
BMRN
多$2.9M
$56.0M
两年增速更快
BMRN
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $682.8M |
| 净利润 | $-46.6M | $-32.7M |
| 毛利率 | 68.5% | 17.6% |
| 营业利润率 | -5.1% | -0.5% |
| 净利率 | -5.3% | -4.8% |
| 营收同比 | 17.0% | -0.4% |
| 净利润同比 | -137.3% | 41.6% |
| 每股收益（稀释后） | $-0.22 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRXT
| Q4 25 | $874.6M | $682.8M | ||
| Q3 25 | $776.1M | $671.2M | ||
| Q2 25 | $825.4M | $666.3M | ||
| Q1 25 | $745.1M | $665.4M | ||
| Q4 24 | $747.3M | $685.6M | ||
| Q3 24 | $745.7M | $675.8M | ||
| Q2 24 | $712.0M | $684.9M | ||
| Q1 24 | $648.8M | $690.8M |
净利润BMRNRXT
| Q4 25 | $-46.6M | $-32.7M | ||
| Q3 25 | $-30.7M | $-67.1M | ||
| Q2 25 | $240.5M | $-54.5M | ||
| Q1 25 | $185.7M | $-71.5M | ||
| Q4 24 | $124.9M | $-56.0M | ||
| Q3 24 | $106.1M | $-186.6M | ||
| Q2 24 | $107.2M | $25.0M | ||
| Q1 24 | $88.7M | $-640.6M |
毛利率BMRNRXT
| Q4 25 | 68.5% | 17.6% | ||
| Q3 25 | 82.0% | 19.4% | ||
| Q2 25 | 81.8% | 19.4% | ||
| Q1 25 | 79.7% | 19.1% | ||
| Q4 24 | 81.8% | 19.2% | ||
| Q3 24 | 74.7% | 20.3% | ||
| Q2 24 | 81.7% | 19.2% | ||
| Q1 24 | 80.7% | 19.2% |
营业利润率BMRNRXT
| Q4 25 | -5.1% | -0.5% | ||
| Q3 25 | -6.0% | -5.1% | ||
| Q2 25 | 33.5% | -3.8% | ||
| Q1 25 | 30.0% | -5.8% | ||
| Q4 24 | 21.6% | -4.2% | ||
| Q3 24 | 15.3% | -25.7% | ||
| Q2 24 | 16.9% | -7.9% | ||
| Q1 24 | 13.6% | -94.5% |
净利率BMRNRXT
| Q4 25 | -5.3% | -4.8% | ||
| Q3 25 | -4.0% | -10.0% | ||
| Q2 25 | 29.1% | -8.2% | ||
| Q1 25 | 24.9% | -10.7% | ||
| Q4 24 | 16.7% | -8.2% | ||
| Q3 24 | 14.2% | -27.6% | ||
| Q2 24 | 15.1% | 3.7% | ||
| Q1 24 | 13.7% | -92.7% |
每股收益（稀释后）BMRNRXT
| Q4 25 | $-0.22 | $-0.13 | ||
| Q3 25 | $-0.16 | $-0.28 | ||
| Q2 25 | $1.23 | $-0.23 | ||
| Q1 25 | $0.95 | $-0.31 | ||
| Q4 24 | $0.65 | $-0.20 | ||
| Q3 24 | $0.55 | $-0.82 | ||
| Q2 24 | $0.55 | $0.11 | ||
| Q1 24 | $0.46 | $-2.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $105.8M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $6.1B | $-1.2B |
| 总资产 | $7.6B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRNRXT
| Q4 25 | $1.3B | $105.8M | ||
| Q3 25 | $1.3B | $99.5M | ||
| Q2 25 | $1.2B | $103.9M | ||
| Q1 25 | $1.0B | $128.0M | ||
| Q4 24 | $942.8M | $144.0M | ||
| Q3 24 | $675.4M | $157.1M | ||
| Q2 24 | $972.1M | $190.2M | ||
| Q1 24 | $747.0M | $282.6M |
总债务BMRNRXT
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $3.0B |
股东权益BMRNRXT
| Q4 25 | $6.1B | $-1.2B | ||
| Q3 25 | $6.1B | $-1.2B | ||
| Q2 25 | $6.0B | $-1.1B | ||
| Q1 25 | $5.8B | $-1.1B | ||
| Q4 24 | $5.7B | $-1.0B | ||
| Q3 24 | $5.4B | $-949.7M | ||
| Q2 24 | $5.3B | $-756.2M | ||
| Q1 24 | $5.1B | $-787.2M |
总资产BMRNRXT
| Q4 25 | $7.6B | $2.8B | ||
| Q3 25 | $7.6B | $2.8B | ||
| Q2 25 | $7.5B | $2.9B | ||
| Q1 25 | $7.1B | $3.0B | ||
| Q4 24 | $7.0B | $3.1B | ||
| Q3 24 | $6.9B | $3.1B | ||
| Q2 24 | $7.1B | $3.4B | ||
| Q1 24 | $6.9B | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $59.7M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $56.0M |
| 自由现金流率自由现金流/营收 | 6.7% | 8.2% |
| 资本支出强度资本支出/营收 | 4.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | $90.6M |
8季度趋势，按日历期对齐
经营现金流BMRNRXT
| Q4 25 | $99.6M | $59.7M | ||
| Q3 25 | $368.7M | $70.7M | ||
| Q2 25 | $185.3M | $8.4M | ||
| Q1 25 | $174.4M | $12.6M | ||
| Q4 24 | $185.6M | $54.3M | ||
| Q3 24 | $221.5M | $51.8M | ||
| Q2 24 | $118.8M | $24.1M | ||
| Q1 24 | $47.0M | $-90.3M |
自由现金流BMRNRXT
| Q4 25 | $58.9M | $56.0M | ||
| Q3 25 | $340.2M | $42.7M | ||
| Q2 25 | $168.2M | $-12.4M | ||
| Q1 25 | $157.6M | $4.3M | ||
| Q4 24 | $166.1M | $34.4M | ||
| Q3 24 | $203.0M | $27.3M | ||
| Q2 24 | $97.4M | $-14.5M | ||
| Q1 24 | $20.9M | $-118.4M |
自由现金流率BMRNRXT
| Q4 25 | 6.7% | 8.2% | ||
| Q3 25 | 43.8% | 6.4% | ||
| Q2 25 | 20.4% | -1.9% | ||
| Q1 25 | 21.2% | 0.6% | ||
| Q4 24 | 22.2% | 5.0% | ||
| Q3 24 | 27.2% | 4.0% | ||
| Q2 24 | 13.7% | -2.1% | ||
| Q1 24 | 3.2% | -17.1% |
资本支出强度BMRNRXT
| Q4 25 | 4.7% | 0.5% | ||
| Q3 25 | 3.7% | 4.2% | ||
| Q2 25 | 2.1% | 3.1% | ||
| Q1 25 | 2.3% | 1.2% | ||
| Q4 24 | 2.6% | 2.9% | ||
| Q3 24 | 2.5% | 3.6% | ||
| Q2 24 | 3.0% | 5.6% | ||
| Q1 24 | 4.0% | 4.1% |
现金转化率BMRNRXT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 1.11× | 0.96× | ||
| Q1 24 | 0.53× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
